Terpenoid Therapeutics Inc. molecule is effective against pulmonary fibrosis in a mouse model

A novel small molecule in the Terpenoid Therapeutics Inc. (TTI) pipeline reduces the progression of pulmonary fibrosis in a mouse model that is accepted as a basis for human drug approval for this disease. The results are published as a manuscript titled “Targeting the isoprenoid pathway to abrogate progression of pulmonary fibrosis,” which recently appeared in the journal Free Radical Biology and Medicine. Pulmonary fibrosis is a devastating disease with high morbidity and mortality. The innovative TTI compound affects an important signaling pathway in lung macrophages that reduces progression of the disease.

Get the full article…

Bookmark the permalink.

Comments are closed.